Skip to main content
Premium Trial:

Request an Annual Quote

Analyst Downgrades Genomic Health for Lackluster Seasonal Oncotype DX Growth

NEW YORK (GenomeWeb News) - An analyst for financial services firm Cantor Fitzgerald has downgraded Genomic Health’s stock to a ‘hold’ from a ‘buy’ based on the company’s third-quarter earnings, which were released on Wednesday.
 
The analyst’s report said growth in Oncotype Dx sales were less than expected within seasonal variation.  
 
As GenomeWeb Daily News reported, Genomic Health reported that third-quarter revenue growth grew 124 percent to $15.9 million while the firm's net loss narrowed 11 percent to $7.3 million.  

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.